WO2008077958A3 - Soluble urokinase plasminogen activator receptor (supar) as marker for diseases - Google Patents

Soluble urokinase plasminogen activator receptor (supar) as marker for diseases Download PDF

Info

Publication number
WO2008077958A3
WO2008077958A3 PCT/EP2007/064497 EP2007064497W WO2008077958A3 WO 2008077958 A3 WO2008077958 A3 WO 2008077958A3 EP 2007064497 W EP2007064497 W EP 2007064497W WO 2008077958 A3 WO2008077958 A3 WO 2008077958A3
Authority
WO
WIPO (PCT)
Prior art keywords
supar
marker
plasminogen activator
diseases
urokinase plasminogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/064497
Other languages
French (fr)
Other versions
WO2008077958A2 (en
Inventor
Jesper Eugen-Olsen
Steen B Haugaard
Ove Andersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hvidovre Hospital
Original Assignee
Hvidovre Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/520,718 priority Critical patent/US8815519B2/en
Priority to GB0912351.4A priority patent/GB2461410C/en
Priority to CA2674521A priority patent/CA2674521C/en
Priority to DK07858108.9T priority patent/DK2115478T3/en
Priority to AU2007337996A priority patent/AU2007337996B2/en
Priority to ES07858108.9T priority patent/ES2456043T3/en
Application filed by Hvidovre Hospital filed Critical Hvidovre Hospital
Priority to EP07858108.9A priority patent/EP2115478B1/en
Publication of WO2008077958A2 publication Critical patent/WO2008077958A2/en
Publication of WO2008077958A3 publication Critical patent/WO2008077958A3/en
Anticipated expiration legal-status Critical
Priority to US14/312,298 priority patent/US9645157B2/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention concerns a marker for low-grade inflammation and metabolic syndrome (MS) and MS-related diseases and/or low-grade inflammation-related diseases such as cardiovasculardisease, ischemic heart disease and type 2 diabetes. More particularly it concerns the measurement of the concentration of soluble urokinase plasminogen activator receptor (suPAR) in human biological fluids (sputum, cystic fluid, ascites, serum, plasma, urine) as a tool of diagnosing and/or prognosticating low-grade inflammation and metabolic syndrome and the risk of development of the related diseases such as cancer, cardiovascular disease, ischemic heart disease and type 2 diabetes.
PCT/EP2007/064497 2006-12-22 2007-12-21 Soluble urokinase plasminogen activator receptor (supar) as marker for diseases Ceased WO2008077958A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US12/520,718 US8815519B2 (en) 2006-12-22 2007-12-12 Method for predicting cancer and other diseases
CA2674521A CA2674521C (en) 2006-12-22 2007-12-21 Method and tool for predicting cardiovascular diseases
DK07858108.9T DK2115478T3 (en) 2006-12-22 2007-12-21 Soluble urokinase plasminogen aktivatorreceptor (suPAR) as a predictive marker of cardiovascular diseases
AU2007337996A AU2007337996B2 (en) 2006-12-22 2007-12-21 Soluble urokinase plasminogen activator receptor (suPAR) as marker for diseases
ES07858108.9T ES2456043T3 (en) 2006-12-22 2007-12-21 Soluble urokinase plasminogen activator receptor (suPAR) as a predictive marker of cardiovascular diseases
GB0912351.4A GB2461410C (en) 2006-12-22 2007-12-21 Method and tool for predicting cancer and other diseases
EP07858108.9A EP2115478B1 (en) 2006-12-22 2007-12-21 Soluble urokinase plasminogen activator receptor (suPAR) as predictive marker for cardiovascular diseases
US14/312,298 US9645157B2 (en) 2006-12-22 2014-06-23 Methods of selecting and treating subjects with low-grade inflammation and metabolic disorders

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US87683806P 2006-12-22 2006-12-22
DKPA200601709 2006-12-22
DKPA200601709 2006-12-22
US60/876,838 2006-12-22
US94707407P 2007-06-29 2007-06-29
DKPA200700956 2007-06-29
DKPA200700956 2007-06-29
US60/947,074 2007-06-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/520,718 A-371-Of-International US8815519B2 (en) 2006-12-22 2007-12-12 Method for predicting cancer and other diseases
US14/312,298 Division US9645157B2 (en) 2006-12-22 2014-06-23 Methods of selecting and treating subjects with low-grade inflammation and metabolic disorders

Publications (2)

Publication Number Publication Date
WO2008077958A2 WO2008077958A2 (en) 2008-07-03
WO2008077958A3 true WO2008077958A3 (en) 2009-04-02

Family

ID=39358030

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/064497 Ceased WO2008077958A2 (en) 2006-12-22 2007-12-21 Soluble urokinase plasminogen activator receptor (supar) as marker for diseases

Country Status (15)

Country Link
US (2) US8815519B2 (en)
EP (2) EP2500730B1 (en)
AU (1) AU2007337996B2 (en)
CA (1) CA2674521C (en)
CY (1) CY1120296T1 (en)
DK (2) DK2500730T3 (en)
ES (2) ES2670711T3 (en)
GB (1) GB2461410C (en)
HU (1) HUE037758T2 (en)
LT (1) LT2500730T (en)
PL (1) PL2500730T3 (en)
PT (1) PT2500730T (en)
SI (1) SI2500730T1 (en)
TR (1) TR201807733T4 (en)
WO (1) WO2008077958A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815519B2 (en) * 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
US9345739B2 (en) 2007-11-08 2016-05-24 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
EP3358354B1 (en) 2008-01-18 2020-07-15 President and Fellows of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
ES2642793T3 (en) * 2008-11-06 2017-11-20 University Of Miami Role of soluble uPAR in the pathogenesis of proteinuric renal disease
US8349256B2 (en) * 2008-11-21 2013-01-08 Sysmex Corporation Blood cell analyzer, blood cell analyzing method, and computer program product
US20130273154A1 (en) * 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
US20130203624A1 (en) 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
MX382244B (en) 2010-07-23 2025-03-13 Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
EP2596349B1 (en) 2010-07-23 2017-12-13 President and Fellows of Harvard College Methods of detecting cardiovascular diseases or conditions
CA2806293A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
SG10201505724SA (en) 2010-07-23 2015-09-29 Harvard College Methods of detecting diseases or conditions using phagocytic cells
EP2707055B1 (en) 2011-05-09 2019-10-23 The University of Miami Reducing soluble urokinase receptor in the circulation
EP2637023A1 (en) * 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease
SG11201408383SA (en) 2012-06-15 2015-01-29 Harry Stylli Methods of detecting diseases or conditions using circulating diseased cells
CN104603289A (en) 2012-06-15 2015-05-06 哈里·斯泰利 Methods of detecting a disease or condition
WO2014012043A1 (en) * 2012-07-13 2014-01-16 Baylor Research Institute Urinary triaosylceramide (gb3) as a risk factor in non-fabry heart disease subjects
US20140188442A1 (en) * 2012-12-27 2014-07-03 Pearson Education, Inc. System and Method for Selecting Predictors for a Student Risk Model
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
EP4202441A3 (en) 2013-03-09 2023-07-26 Immunis.AI, Inc. Gene expression profile in macrophages for the diagnosis of cancer
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
WO2016201573A1 (en) * 2015-06-16 2016-12-22 Quantum Dental Technologies Inc. System and method of monitoring consumable use based on correlations with diagnostic testing
WO2017075268A1 (en) 2015-10-27 2017-05-04 Abbott Laboratories Troponin i and soluble urokinase receptor detection for determining the risk of cardiovascular disease
FI20177098A1 (en) * 2017-08-29 2019-03-01 Leppaeluoto Juhani Procedures and device arrangements for determining thresholds for physical activity that reduce the risks of diabetes, cardiovascular disease, inflammation, dementia and mortality in sedentary people
GB201802795D0 (en) * 2018-02-21 2018-04-04 Virogates As Patient assessment method
RU2706548C1 (en) * 2019-01-31 2019-11-19 федеральное государственное бюджетное образовательное учреждение высшего образования "Тверской государственный медицинский университет" Министерства здравоохранения Российской Федерации Diagnostic technique for hiv infection stages
WO2020206129A1 (en) * 2019-04-02 2020-10-08 The Regents Of The University Of Michigan Use of soluble urokinase plasminogen activator receptor levels in the management of patients with cardiovascular disease
CN111128398B (en) * 2020-03-30 2020-08-14 广州地理研究所 Epidemic disease infected person number estimation method based on population migration big data
JP2023520941A (en) * 2020-04-08 2023-05-22 ヴィロゲーツ エー／エス SARS-COV-2 infection risk assessment method
CN112630442A (en) * 2020-11-03 2021-04-09 浙江大学 Plasma soluble urokinase type plasminogen activator receptor and application thereof
EP4490511A2 (en) * 2022-03-07 2025-01-15 Rush University Medical Center Novel treatment of diabetes and kidney disease by inhibition of d2d3 a proteolytic upar protein
CN114334170A (en) * 2022-03-14 2022-04-12 天津云检医学检验所有限公司 Metabolic age prediction model and application thereof in colorectal cancer diagnosis
CN114783607B (en) * 2022-05-10 2023-06-23 中南大学湘雅医院 A risk prediction model for surgical blood transfusion and its network calculator construction method
CN116106535B (en) * 2023-04-11 2023-08-11 南京品生医学检验实验室有限公司 Application of biomarker combination in the preparation of breast cancer prediction products

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248712B1 (en) * 1989-04-07 2001-06-19 Cancerforskningsfondet Af 1989 Urokinase-type plasminogen activator receptor
WO2002058714A2 (en) * 2001-01-25 2002-08-01 Fondazione Centro San Raffaele Del Monte Tabor Methods and agents modulating upa/upar activity
WO2003031650A2 (en) * 2001-10-08 2003-04-17 Bayer Healthcare Ag Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
WO2005116077A2 (en) * 2004-05-25 2005-12-08 Attenuon, Llc LIGANDS BINDING THE COMPLEX OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (uPA) AND ITS RECEPTOR (uPAR) THAT INHIBIT DOWNSTREAM uPAR INTERACTIONS: IDENTIFICATION AND USE IN DIAGNOSIS OR THERAPY

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0015936A (en) * 1999-11-25 2002-09-17 Jesper Eugen-Olsen Diagnostic or prognostic method of HIV infection in an individual
US8815519B2 (en) * 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248712B1 (en) * 1989-04-07 2001-06-19 Cancerforskningsfondet Af 1989 Urokinase-type plasminogen activator receptor
WO2002058714A2 (en) * 2001-01-25 2002-08-01 Fondazione Centro San Raffaele Del Monte Tabor Methods and agents modulating upa/upar activity
WO2003031650A2 (en) * 2001-10-08 2003-04-17 Bayer Healthcare Ag Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
WO2005116077A2 (en) * 2004-05-25 2005-12-08 Attenuon, Llc LIGANDS BINDING THE COMPLEX OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR (uPA) AND ITS RECEPTOR (uPAR) THAT INHIBIT DOWNSTREAM uPAR INTERACTIONS: IDENTIFICATION AND USE IN DIAGNOSIS OR THERAPY

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANDERSEN O ET AL: "Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy.", J MED VIROL, vol. 80, no. 2, February 2008 (2008-02-01), pages 209 - 216, XP008094314 *
FLORDELLIS C S ET AL: "New therapeutic options for the metabolic syndrome: what's next?", TRENDS ENDOCRINOL METABOL, vol. 16, no. 6, August 2005 (2005-08-01), pages 254 - 260, XP004996563 *
KOH ET AL: "Inflammatory Markers and the Metabolic Syndrome", J AM COLLEGE CARDIOL, vol. 46, no. 11, 6 December 2005 (2005-12-06), pages 1978 - 1985, XP005191479 *
MIZUKAMI I F ET AL: "Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo.", BLOOD, vol. 86, no. 1, 1 July 1995 (1995-07-01), pages 203 - 211, XP002446706 *
OSTROWSKI S R ET AL: "High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients.", J ACQUIR IMMUNE DEFIC SYNDR, vol. 39, no. 1, 1 May 2005 (2005-05-01), pages 23 - 31, XP002488617 *
OSTROWSKI S R ET AL: "Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy", SCAND J IMMUNOL, vol. 63, no. 6, June 2006 (2006-06-01), pages 478 - 486, XP002446704 *
OSTROWSKI S R ET AL: "Soluble Urokinase Receptor Levels in Plasma during 5 Years of Highly Active Antiretroviral Therapy in HIV-1-Infected Patients", J ACQUIR IMMUNE DEFIC SYNDR, vol. 35, no. 4, 1 April 2004 (2004-04-01), pages 337 - 342, XP002446705 *
SLOAND E M ET AL: "A role for plasma urokinase plasminogen activator receptor (uPAR) in thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)", BLOOD, vol. 104, no. 11, Part 1, November 2004 (2004-11-01), & 46TH ANN MEETING AM SOC HEMATOL; SAN DIEGO, CA, USA; DEC 04 -07, 2004, pages 84A, XP008099893 *
SVENDSEN M N ET AL: "Preoperative concentrations of suPAR and MBL proteins are associated with the development of pneumonia after elective surgery for colorectal cancer.", SURGICAL INFECTIONS, vol. 7, no. 5, October 2006 (2006-10-01), pages 463 - 471, XP002446703 *

Also Published As

Publication number Publication date
GB2461410A (en) 2010-01-06
US20100098705A1 (en) 2010-04-22
GB2461410C (en) 2018-06-20
CY1120296T1 (en) 2019-07-10
ES2456043T3 (en) 2014-04-21
EP2115478A2 (en) 2009-11-11
WO2008077958A2 (en) 2008-07-03
LT2500730T (en) 2018-05-10
GB0912351D0 (en) 2009-08-26
US20140370527A1 (en) 2014-12-18
HUE037758T2 (en) 2018-09-28
DK2115478T3 (en) 2014-03-10
AU2007337996B2 (en) 2013-03-14
EP2500730B1 (en) 2018-03-07
DK2500730T3 (en) 2018-05-28
US8815519B2 (en) 2014-08-26
EP2500730A1 (en) 2012-09-19
PT2500730T (en) 2018-05-28
CA2674521C (en) 2022-06-14
CA2674521A1 (en) 2008-07-03
AU2007337996A1 (en) 2008-07-03
EP2115478B1 (en) 2014-01-22
GB2461410B (en) 2011-06-29
ES2670711T3 (en) 2018-05-31
US9645157B2 (en) 2017-05-09
PL2500730T3 (en) 2018-08-31
TR201807733T4 (en) 2018-06-21
SI2500730T1 (en) 2018-08-31

Similar Documents

Publication Publication Date Title
GB2461410A (en) Soluble urokinase plasminogen activator receptor (SUPAR) as marker for diseases
WO2008131361A3 (en) Biosensors for measuring analytes in the interstitial fluid
WO2005114190A3 (en) Methods of identifying biomarkers
WO2004111273A3 (en) Gene expression markers for response to egfr inhibitor drugs
WO2008021192A3 (en) Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
WO2004076679A3 (en) Serum macrophage migration inhibitory factor (mif) as marker for prostate cancer
WO2005044091A3 (en) Diagnostic and therapeutic methods and compositions involving pten and breast cancer
WO2009017861A3 (en) Analyte detection using autocatalytic chain reactions
WO2009012140A3 (en) Drug selection for lung cancer therapy using antibody-based arrays
WO2007098444A3 (en) Methods for analysis of extracellular rna species
WO2006026601A3 (en) Homogeneous enzyme immunoassay for oral fluid
WO2007039290A3 (en) Methods and nucleic acids for the analysis of gene expression associated with the prognosis of cell proliferative disorders
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
WO2008008708A3 (en) Lung cancer diagnostic assay
WO2008027162A3 (en) 129xe biosensors and their use
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
WO2006052788A3 (en) Detection of activation of endothelial cells as surrogate marker for angiogenesis
WO2008020823A3 (en) Cooperative reporter systems, components, and methods for analyte detection
WO2006033664A8 (en) Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
WO2008081455A3 (en) Detection of analytes
WO2008082673A8 (en) Companion diagnostic assays for cancer therapy
WO2005121362A3 (en) Method for selectively quantifying vegf isoforms in a biological sample and uses thereof.
WO2006119326A3 (en) Oligonucleotide probe/primer compositions and methods for polynucleotide detection
WO2003048734A3 (en) Detection of matrix metalloproteinase rna in plasma and serum
WO2007134274A3 (en) Antibodies to urokinase- type plasminogen activator receptor(upar)bind cancer stem cells: use in diagnosis and therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07858108

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007337996

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2674521

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007337996

Country of ref document: AU

Date of ref document: 20071221

Kind code of ref document: A

Ref document number: 0912351

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20071221

WWE Wipo information: entry into national phase

Ref document number: 0912351.4

Country of ref document: GB

Ref document number: 2007858108

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12520718

Country of ref document: US